HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.

AbstractINTRODUCTION:
There is still insufficient data concerning the clinical effects of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease (CKD).
METHODS:
This study included non-diabetic CKD patients with urinary protein excretion (UPE) of 1.0 g/gCr or more in spite of long-term treatment with renin-angiotensin system (RAS) inhibitors. The clinical effects of eplerenone (25-50 mg/day) were investigated for 12 months.
RESULTS:
Eplerenone treatment was associated with a 38% reduction in UPE after 12 months. There was only a slight increase in the serum potassium level. The reduction of proteinuria was observed more prominently in patients with modestly impaired renal function than in those with preserved renal function at baseline.
CONCLUSION:
The long-term administration of low-dose eplerenone was effective and safe for the treatment of non-diabetic CKD patients who showed persistent proteinuria in spite of therapy with RAS inhibitors.
AuthorsNobuo Tsuboi, Tetsuya Kawamura, Hideo Okonogi, Takeo Ishii, Tatsuo Hosoya
JournalJournal of the renin-angiotensin-aldosterone system : JRAAS (J Renin Angiotensin Aldosterone Syst) Vol. 13 Issue 1 Pg. 113-7 (Mar 2012) ISSN: 1752-8976 [Electronic] England
PMID21729991 (Publication Type: Journal Article)
Chemical References
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
  • Eplerenone
Topics
  • Adult
  • Aged
  • Blood Pressure (drug effects)
  • Diabetic Nephropathies (complications, drug therapy, physiopathology)
  • Eplerenone
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Kidney Failure, Chronic (complications, drug therapy, physiopathology)
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists (pharmacology, therapeutic use)
  • Multivariate Analysis
  • Proteinuria (complications, drug therapy, physiopathology)
  • Spironolactone (analogs & derivatives, pharmacology, therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: